@Dr_AmerZeidan@Papa_Heme 15-20% appears to be over simplification. HCT-CI, CHARM scores can provide better estimate & discussions. 15-20% can be higher for healthy patient with no comorbdities and lower for patient with poor PS and comorbidities. I plug in best case scenario to CHARM & TRM < than 10%.
@nehban@jelevenson Hi, interesting discussion here. I was curious if there any update after that or anecdotes from personal experience? I am trying to find data of dexrazoxane use with infusion Doxorubicin.
Today is World Marrow Donor Day, a day dedicated to saying #ThankYouDonor to all who have donated marrow, cord blood or are on the registry. Learn more about how you can participate: https://t.co/tLR17QI7bp #WWMDD24@MarrowDonorDay
#AMLsm 70yr healthy man developed pancytopenia, diagnosed with adverse risk AML [JAK2 V617F VAF ~ 40%,rest NGS negative, complex karyotype with 5 q(-), 20 q(-), refractory to 7+3 [100 and 60], is day 12 of Aza-Ven [75-100], blast count trending up after 7 days of Aza. Next step?
@Dr_AmerZeidan seems clearly refractory to aza-ven the way blast count is rising. Day 11, WBC count is 3.1 in blood and absolute blast count is 2.6. would you agree, clear progression? no bone marrow done. Ven is 100, due to posa.
A 65-year-old man with pancytopenia was found to have MDS on bone marrow biopsy with 3-4% CD34 blasts, normal cytogenetics, NGS BCOR 5%, SRSF2 50%, & RUNX1 5%. IPSS-R int, IPSS-M high. Transplant eligible. CBC stable, on monitoring. Would u recommend a transplant?
#MDSmm#BMTsm
⚡️Applications are now open!!⚡️
🎊Be a part of a vibrant community where you can enhance your knowledge in nephrology, develop social media skills, and contribute in shaping the future of nephrology education and outreach.🎉
https://t.co/iGDKox2xtY
Hey #CARTsm#mmsm#lympsm tweeps. Pl vote. 😊🙏
How far patients are recommended to stay from the CART center, for the first thirty days of receiving the CART product in the hospital? Per your institution/transplant unit policy. Thanks.